Vivian P Bykerk1, Nancy Shadick, Michelle Frits, Clifton O Bingham, Iain Jeffery, Christine Iannaccone, Michael Weinblatt, Daniel H Solomon. 1. From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA.
Abstract
OBJECTIVE: To describe the frequency, duration, and management of flares as reported by patients with rheumatoid arthritis (RA). METHODS: Data were collected in a prospective observational study of patients with RA recruited from a single academic center and treated according to the rheumatologists' discretion. Every 6 months, patients reported the number and duration of RA flares and described how these were managed in terms of adding or changing medication and use of nonpharmacologic strategies. RESULTS: Of patients who reported flares at least once during the study, 74% reported having flares 6 months prior to study entry and 59% reported flares prior to the first 6-month visit. At subsequent visits, 54-57% reported having > 1 flare. Thirty percent of patients in remission reported flares. Flare duration lasted ≥ 2 weeks in 30%, 1-2 weeks in 13%, and < 1 week in 57%. Forty percent reported medication changes at the time of their flare; 16% changed medication and used nonpharmacologic strategies and 26% of patients reported no changes in treatment as a result of flares. Longer duration of flare was associated with changes in disease-modifying therapy. CONCLUSION: Patients with RA experienced flares more often when noted to be in higher disease activity states than when in remission and reported changes in disease-modifying antirheumatic drugs or biologics more frequently when flares were of longer duration. There is a need to prospectively study symptom intensity and duration of flare in relation to disease activity and consider self-management strategies in the development of a measure of flare.
OBJECTIVE: To describe the frequency, duration, and management of flares as reported by patients with rheumatoid arthritis (RA). METHODS: Data were collected in a prospective observational study of patients with RA recruited from a single academic center and treated according to the rheumatologists' discretion. Every 6 months, patients reported the number and duration of RA flares and described how these were managed in terms of adding or changing medication and use of nonpharmacologic strategies. RESULTS: Of patients who reported flares at least once during the study, 74% reported having flares 6 months prior to study entry and 59% reported flares prior to the first 6-month visit. At subsequent visits, 54-57% reported having > 1 flare. Thirty percent of patients in remission reported flares. Flare duration lasted ≥ 2 weeks in 30%, 1-2 weeks in 13%, and < 1 week in 57%. Forty percent reported medication changes at the time of their flare; 16% changed medication and used nonpharmacologic strategies and 26% of patients reported no changes in treatment as a result of flares. Longer duration of flare was associated with changes in disease-modifying therapy. CONCLUSION:Patients with RA experienced flares more often when noted to be in higher disease activity states than when in remission and reported changes in disease-modifying antirheumatic drugs or biologics more frequently when flares were of longer duration. There is a need to prospectively study symptom intensity and duration of flare in relation to disease activity and consider self-management strategies in the development of a measure of flare.
Authors: Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts Journal: Arthritis Care Res (Hoboken) Date: 2018-04-16 Impact factor: 4.794
Authors: Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Katie Bechman; Lieke Tweehuysen; Toby Garrood; David L Scott; Andrew P Cope; James B Galloway; Margaret H Y Ma Journal: J Rheumatol Date: 2018-09-01 Impact factor: 4.666
Authors: Elena Myasoedova; Cynthia S Crowson; Rachel E Giblon; Kathleen McCarthy-Fruin; Daniel E Schaffer; Kerry Wright; Eric L Matteson; John M Davis Journal: Clin Rheumatol Date: 2019-07-01 Impact factor: 2.980
Authors: Lisa G Rider; Christine G Parks; Jesse Wilkerson; Adam I Schiffenbauer; Richard K Kwok; Payam Noroozi Farhadi; Sarvar Nazir; Rebecca Ritter; Emily Sirotich; Kevin Kennedy; Maggie J Larche; Mitchell Levine; Sebastian E Sattui; Jean W Liew; Carly O Harrison; Tarin T Moni; Aubrey K Miller; Michael Putman; Jonathan Hausmann; Julia F Simard; Jeffrey A Sparks; Frederick W Miller Journal: Rheumatology (Oxford) Date: 2022-06-28 Impact factor: 7.046
Authors: Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy Journal: J Rheumatol Date: 2014-03-01 Impact factor: 4.666
Authors: Irina A Tikhonova; Huiqin Yang; Segun Bello; Andrew Salmon; Sophie Robinson; Mohsen Rezaei Hemami; Sophie Dodman; Andriy Kharechko; Richard C Haigh; Meghna Jani; Timothy J McDonald; Martin Hoyle Journal: Health Technol Assess Date: 2021-02 Impact factor: 4.014
Authors: Iris M Markusse; Linda Dirven; Andreas H Gerards; Johannes H L M van Groenendael; H Karel Ronday; Pit J S M Kerstens; Willem F Lems; Tom W J Huizinga; Cornelia F Allaart Journal: Arthritis Res Ther Date: 2015-08-31 Impact factor: 5.156